DVAX
Price
$10.27
Change
+$0.11 (+1.08%)
Updated
Jul 3 closing price
Capitalization
1.62B
25 days until earnings call
ESALF
Price
$29.31
Change
-$0.00 (-0.00%)
Updated
Jun 16 closing price
Capitalization
18.29B
Interact to see
Advertisement

DVAX vs ESALF

Header iconDVAX vs ESALF Comparison
Open Charts DVAX vs ESALFBanner chart's image
Dynavax Technologies
Price$10.27
Change+$0.11 (+1.08%)
Volume$511.14K
Capitalization1.62B
Eisai
Price$29.31
Change-$0.00 (-0.00%)
Volume$1.53K
Capitalization18.29B
DVAX vs ESALF Comparison Chart in %
Loading...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DVAX vs. ESALF commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a Hold and ESALF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (DVAX: $10.27 vs. ESALF: $29.31)
Brand notoriety: DVAX and ESALF are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: DVAX: 25% vs. ESALF: 169%
Market capitalization -- DVAX: $1.62B vs. ESALF: $18.29B
DVAX [@Pharmaceuticals: Other] is valued at $1.62B. ESALF’s [@Pharmaceuticals: Other] market capitalization is $18.29B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DVAX’s FA Score shows that 0 FA rating(s) are green whileESALF’s FA Score has 2 green FA rating(s).

  • DVAX’s FA Score: 0 green, 5 red.
  • ESALF’s FA Score: 2 green, 3 red.
According to our system of comparison, ESALF is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DVAX’s TA Score shows that 4 TA indicator(s) are bullish while ESALF’s TA Score has 7 bullish TA indicator(s).

  • DVAX’s TA Score: 4 bullish, 3 bearish.
  • ESALF’s TA Score: 7 bullish, 1 bearish.
According to our system of comparison, ESALF is a better buy in the short-term than DVAX.

Price Growth

DVAX (@Pharmaceuticals: Other) experienced а +3.32% price change this week, while ESALF (@Pharmaceuticals: Other) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.02%. For the same industry, the average monthly price growth was +2.94%, and the average quarterly price growth was +92.60%.

Reported Earning Dates

DVAX is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.02% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ESALF($18.3B) has a higher market cap than DVAX($1.62B). ESALF has higher P/E ratio than DVAX: ESALF (46.30) vs DVAX (31.63). ESALF YTD gains are higher at: 14.101 vs. DVAX (-19.577). ESALF has higher annual earnings (EBITDA): 87.3B vs. DVAX (9.67M). ESALF has more cash in the bank: 268B vs. DVAX (742M). DVAX has less debt than ESALF: DVAX (257M) vs ESALF (126B). ESALF has higher revenues than DVAX: ESALF (744B) vs DVAX (232M).
DVAXESALFDVAX / ESALF
Capitalization1.62B18.3B9%
EBITDA9.67M87.3B0%
Gain YTD-19.57714.101-139%
P/E Ratio31.6346.3068%
Revenue232M744B0%
Total Cash742M268B0%
Total Debt257M126B0%
FUNDAMENTALS RATINGS
DVAX vs ESALF: Fundamental Ratings
DVAX
ESALF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
13
Undervalued
PROFIT vs RISK RATING
1..100
7389
SMR RATING
1..100
935
PRICE GROWTH RATING
1..100
6355
P/E GROWTH RATING
1..100
9893
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESALF's Valuation (13) in the null industry is somewhat better than the same rating for DVAX (69) in the Biotechnology industry. This means that ESALF’s stock grew somewhat faster than DVAX’s over the last 12 months.

DVAX's Profit vs Risk Rating (73) in the Biotechnology industry is in the same range as ESALF (89) in the null industry. This means that DVAX’s stock grew similarly to ESALF’s over the last 12 months.

ESALF's SMR Rating (5) in the null industry is significantly better than the same rating for DVAX (93) in the Biotechnology industry. This means that ESALF’s stock grew significantly faster than DVAX’s over the last 12 months.

ESALF's Price Growth Rating (55) in the null industry is in the same range as DVAX (63) in the Biotechnology industry. This means that ESALF’s stock grew similarly to DVAX’s over the last 12 months.

ESALF's P/E Growth Rating (93) in the null industry is in the same range as DVAX (98) in the Biotechnology industry. This means that ESALF’s stock grew similarly to DVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DVAXESALF
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
53%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
71%
Bullish Trend 4 days ago
46%
Momentum
ODDS (%)
Bearish Trend 4 days ago
77%
Bullish Trend 4 days ago
44%
MACD
ODDS (%)
N/A
Bullish Trend 4 days ago
45%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
37%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
47%
Advances
ODDS (%)
Bullish Trend 4 days ago
75%
N/A
Declines
ODDS (%)
Bearish Trend 20 days ago
80%
N/A
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
73%
Bearish Trend 4 days ago
70%
Aroon
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PGBEX48.070.66
+1.39%
Principal Blue Chip R3
MBCGX20.800.22
+1.07%
MassMutual Blue Chip Growth A
SUTAX16.450.15
+0.92%
AB Sustainable US Thematic A
NMUEX11.050.10
+0.91%
Neuberger Berman Multi-Cap Opp E
FAMEX60.040.40
+0.67%
FAM Dividend Focus Fund Investor

DVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ESPR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ESPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
+1.08%
ESPR - DVAX
34%
Loosely correlated
+1.74%
SUPN - DVAX
34%
Loosely correlated
-0.28%
ALKS - DVAX
33%
Loosely correlated
-0.52%
AMRX - DVAX
30%
Poorly correlated
+0.60%
AMPH - DVAX
29%
Poorly correlated
-1.61%
More

ESALF and

Correlation & Price change

A.I.dvisor tells us that ESALF and ESAIY have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESALF and ESAIY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESALF
1D Price
Change %
ESALF100%
N/A
ESAIY - ESALF
30%
Poorly correlated
+0.28%
KHTRF - ESALF
27%
Poorly correlated
+4.50%
DVAX - ESALF
22%
Poorly correlated
+1.08%
BLMH - ESALF
20%
Poorly correlated
+1.89%
DBCCF - ESALF
15%
Poorly correlated
-4.24%
More